Key References Sikiric P, et al
Questi benefici per non sembrerebbero essere stati analizzati e confermati in letteratura
SOLIQUA 100/33 (an insulin-containing product), or any insulin, should not be used during episodes of hypoglycemia [see CONTRAINDICATIONS ]
Reflecting a growing acceptance of obesity as a legitimate medical condition, at least in the United State, a 2024 employer health benefits survey found that 61% of respondents support expanding Medicare (federal health insurance program primarily for individuals aged 65 and older) coverage beyond treatment for T2DM to include GLP-1 therapies for weight management in overweight individuals (Kaiser Family, F, 2024)
Long-term use combined with a healthy lifestyle is key
For patients interested in maximizing metabolic benefit through multiple pathways without sermorelin, GLP-Squared provides a streamlined, evidence-supported option